работа сделана вовремя, замечаний не было
Информация о работе
Подробнее о работе
Анализ роли генетического варианта c.1320+1G>A гена CDH1 в развитии рака желудка
- 56 страниц
- 2022 год
- 1 просмотр
- 0 покупок
Гарантия сервиса Автор24
Уникальность не ниже 50%
Фрагменты работ
В лаборатории молекулярной генетики и фундаментальной медицины проведено секвенирование экзома и у одного пациента из девяти обнаружена мутация в гене CDH1, который является патогенной по результатам анализа большинства баз данных.
ВВЕДЕНИЕ 4
1. Обзор литературы 6
1.1. Классификация рака желудка 6
1.2. Эпидемиология рака желудка 9
1.3. Механизмы патогенеза рака желудка 13
1.3.1. Факторы риска развития рака желудка 13
1.3.2. Генетические факторы риска развития рака желудка 16
1.4 Роль гена CDH1 в развитии рака желудка 20
1.4.1 Строение и функции гена CDH1 21
1.4.2. Генетические изменения гена CDH1, ассоциированные с раком желудка 24
2. Материалы и методы исследования 32
2.1. Материалы исследования 32
2.2. Методы исследования 34
2.2.1. Выделение геномной ДНК 34
2.2.2. Полимеразная цепная реакция синтеза ДНК 35
2.2.3. Анализ кривых плавления с высокой разрешающей способностью (HRM) 37
2.2.4. Определение нуклеотидной последовательности методом дидезоксисеквенирования по Сенгеру 37
2.2.6. Электрофорез фрагментов ДНК в полиакриламидном геле (ПААГ) 38
2.2.7. Статистическая обработка полученных результатов 39
3. Результаты исследований и их обсуждение 42
3.1. Ресеквенирование участка экзома, содержащего выявленный в результате экзомного секвенирования генетический вариант c.1320+1G>A гена CDH1 43
3.2. Поиск изменений нуклеотидной последовательности участка, содержащего вариант c.1320+1G>A гена CDH1, в образцах ДНК, выделенных из крови больных раком желудка и здоровых индивидов, а также из опухолевой и здоровой ткани больных раком желудка из Республики Башкортостан 45
3.3. Верифицирование выявленных изменений с помощью секвенирования методом Сэнгера 46
ЗАКЛЮЧЕНИЕ 48
ВЫВОДЫ: 49
СПИСОК ИСПОЛЬЗОВАННЫХ ИСТОЧНИКОВ И ЛИТЕРАТУРЫ 50
Период изготовления: апрель 2022 года.
Учебное заведение: Башкирский Государственный Университет.
Оригинальность по Антиплагиат.ру (бесплатный) составила 72%.
Работы успешно сдана - заказчик претензий не имел.
1. Данилова Н.В., Олейникова Н.А., Мальков П.Г. Классификация эпителиальных опухолей желудка ВОЗ 2019 года, 5-е издание. //Архив патологии. – 2020. – T. 82. - №. 4. – P. 58–69.
2. Каприн А.Д., Старинский В.В, Шахзадова А.О. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность) //М.: МНИОИ им. П.А. Герцена. − 2021. – С. 252.
3. Поддубная И.В., Каприн А.Д., Лядов В.К. Классификация опухолей TNM. 8-я ред. Руководство и атлас. Т. I: Опухоли торакоабдоминальной локализации. //М.: Практическая медицина. - 2018. – С. 424.
4. Рябов А.Б., Соколов В.В., Хомяков В.М., Пирогов С.С., Колобаев И.В., Черемисов В.В. Современные подходы к диагностике и лечению раннего рака желудка. //Онкология. Журнал им. П.А. Герцена. – 2015. – Т. 4. - №. 2. С. 71‑75.
5. Alberto Barchi, Antonio Nouvenne, Ottavia Cavatorta 1, Serena Scida, Chiara Miraglia, Gioacchino Leandro, Tiziana Meschi, Gian Luigi De' Angelis, Francesco Di Mario. Epidemiology of gastric cancer and risk factors. //PubMed. – 2018. – T. 89. – P. 82-87.
6. Araujo-Filho I., Brandao-Neto J. Prevalence of helicobacter pylori infection in advanced gastric carcinoma // Arq. Gastroenterol. – 2006. – T. 43. – P. 288-292.
7. Bamboat Z. M. et al. Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma //Annals of surgical oncology. – 2014. – Т. 21. – №. 5. – P. 1678-1685.
8. Baniak N. et al. Gastric biomarkers: a global review //World journal of surgical oncology. – 2016. – Т. 14. – №. 1. – P. 212.
9. Bray F., Ferlay J., Soerjomataram I. et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. //CA: A Cancer Journal for Clinicians. – 2018. – Р. 1–31.
10. Bustos-Carpinteyro A. R. et al. CDH1 somatic alterations in Mexican patients with diffuse and mixed sporadic gastric cancer //BMC cancer. – 2019. – Т. 19. – №. 1. – Р. 1-9.
11. Caggiari L. et al. Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype //International journal of molecular sciences. – 2017. – Т. 19. – №. 1. – Р. 47.
12. Caldas C., Carneiro F., Lynch H.T. et al. Familial gastric cancer: overview and guidelines for management // J Med Genet. – 1999. – Т. 36. – 873-880.
13. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. //PubMed. – 2014. T. 513. – №. 7517. – P. 202-209.
14. Chia, N-Y., and P. Tan. "Molecular classification of gastric cancer." //Annals of Oncology. – 2016. – Р. 763-769.
15. Choi S. et al. CDH1 mutations in gastric cancers are not associated with family history //Pathology-Research and Practice. – 2020. – Р. 152.
16. Chen T., Jinlin D., Wang F., Yuan Z., Xue J., Lu T., Huang W., Liu Y., Zhang Y. GSTM3 deficiency impedes DNA mismatch repair to promote gastric tumorigenesis via CAND1/NRF2-KEAP1 signaling. //PubMed. – 2022. – T. 10. – P. 4-7.
17. Corso G. et al. Frequency of CDH1 germline mutations in gastric carcinoma coming from high-and low-risk areas: metanalysis and systematic review of the literature //BMC cancer. – 2012. – Т. 12. – №. 1. – P. 8.
18. Crew K. D., Neugut A. I. Epidemiology of gastric cancer //World journal of gastroenterology: WJG. – 2016. – Т. 12. – №. 3. – P. 354.
19. Deng N., et al. A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets //PubMed. – 2019. – P. 3-5.
20. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. //Lyon: International Agency for Research on Cancer. 2020. – 2022.
21. Ganesan K., Ivanova T., Wu Y., et al. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res. – 2008. – Т. 68. - №. 11. – P. 427-428.
22. Hakkaart C. et al. Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand Māori //Familial cancer. – 2019. – Т. 18. – №. 1. – Р. 83-90.
23. Hanazono K., Natsugoe S., Stein H.J., et al. Distribution of p53 mutations in esophageal and gastric carcinomas and the relationship with p53 expression. //Oncol Rep. – 2006. – Т. 15. - №. 4. – P. 821-824.
24. Haot, J. Anatomo-pathological classification of gastric tumors / J. Haot, P. Michel // Acta Gastroenterol. Belg. – 1989. – Т. 52. – №. 3. – P. 340-352.
25. Huynh J. M., Laukaitis C. M. Panel testing reveals nonsense and missense CDH1 mutations in families without hereditary diffuse gastric cancer //Molecular genetics & genomic medicine. – 2017. – Т. 4. – №. 2. – P. 232-236.
26. Hwang S.W., Lee D.H., Lee S.H. et al. Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography //J Gastroenterol Hepatol. – 2010. – Т. 25. – Р. 512-518.
27. ImaiK., YamamotoH. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics //Carcinogenesis. – 2008. – Т. 29. – P. 673-680.
28. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 //Gastric Cancer. - 2017. – Р. 1–19.
29. Jihenne Ben Aissa-Haj, Maria Kabbage, Houcemeddine Othmen, Patrick Saulnier, Haifa Tounsi Kettiti, Amira Jaballah-Gabteni, Azer Ferah, Mouna Medhioub, Amal Khsiba, Moufida Mahmoudi, Afifa Maaloul, Sonia Ben Nasr, Emna Chelbi, Sonia Abdelhak, M. Samir Boubaker, Mohamed Mousaddak Azzouz, and Etienne Rouleau. CDH1 Germline Variants in a Tunisian Cohort with Hereditary Diffuse Gastric Carcinoma. //PubMed. – 2022. – T. 13. – P. 4.
30. Joana Figueired, Fátima Mercadillo, Soraia Melo, Alicia Ba
31. rroso, Margarida Gonçalves, José Díaz-Tasende, Patrícia Carneiro, Luis Robles, Francisco Colina, Carolina Ibarrola, José Perea, Eurico Morais-de-Sá, Raquel Seruca, and Miguel Urioste. Germline CDH1 G212E Missense Variant: Combining Clinical, In Vitro and In Vivo Strategies to Unravel Disease Burden. //PubMed. – 2021. – №. 13. – Р. 2-3.
32. Julia C., Valleron A. J. Louis-René Villermé (1782–1863), a pioneer in social epidemiology: re-analysis of his data on comparative mortality in Paris in the early 19th century //Journal of Epidemiology & Community Health. – 2011. – Т. 65. – №. 8. – P. 666-670.
33. Kakiuchi M, Nishizawa T, Ueda H, et al. Recurrent gainof-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. – 2014. – T. 46. – P.583-587.
34. Karimi P. et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention //Cancer Epidemiology and Prevention Biomarkers. – 2014. – Т. 23. – №. 5. – С. 700-713.
35. Karimi P. et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention //Cancer Epidemiology and Prevention Biomarkers. – 2016. – Т. 23. – №. 5. – P. 700-713.
36. Karimi P., Islami F., Anandasabapathy S. et al. Gastric cancer: descriptive epidemiology, risk factors, screening and prevention //Cancer Epidemiol Biomarkers Prev. – 2016. – T. 23. – P. 700-713.
37. Kelley J. R., Duggan J. M. Gastric cancer epidemiology and risk factors //Journal of clinical epidemiology. – 2003. – Т. 56. – №. 1. – P. 1-9.
38. Kim J., Fox C., Peng S., et al. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Invest. – 2017. – T. 124. – №. 12. – P. 5145-5158.
39. Kim K. M. et al. Genetic classification of intestinal-type and diffuse-type gastric cancers based on chromosomal loss and microsatellite instability //Virchows Archiv. – 2003. – Т. 443. – №. 4. – P. 491-500
40. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification // Acta Pathol Microbiol Scand. – 1965. – T. 64. – P. 31-49.
41. Lee Y.Y., Derakhshan M.H. Environmental and lifestyle risk factors of gastric cancer // Arch Iran Med. – 2017. – T. 16. – P. 358-365.
42. Li D., Lo W., Rudloff U. Merging perspectives: genotype-directed molecular therapy for hereditary diffuse gastric cancer (HDРЖ) and E-cadherin–EGFR crosstalk //Clinical and translational medicine. – 2018. – Т. 7. – №. 1. – P. 1-6.
43. Liu X., Chu K.M. E-cadherin and gastric cancer: cause, consequence, and applications. Biomed Res Int. – 2017. – T. 63
44. Lo W. et al. Associations of CDH1 germline variant location and cancer phenotype in families with hereditary diffuse gastric cancer (HDРЖ) //Journal of medical genetics. – 2019. – Т. 56. – №. 6. – P. 370-379.
45. Luo W. et al. CDH1 gene and hereditary diffuse gastric cancer syndrome: Molecular and histological alterations and implications for diagnosis and treatment //Frontiers in pharmacology. – 2018. – Т. 9. – P. 1421.
46. Majid Kheirollahi1, Maryam Saneipour, Abbas Moridnia. Germline likely pathogenic variants in ataxia-telangiectasia-mutated gene in an Iranian family with hereditary diffuse gastric cancer without CDH1 mutation. //PubMed – 2021. – Т. 6. – P. 1434-1437.
47. Mohadeseh Naghi Vishteh, Mehrdad Zeinalian, Majid Kheirollahi, Amirreza Javadi Mamaghani, Mohammad Ali Zolfaghari, Aliyar Mirzapour, Meisam Barati, and Seyed Javad Seyed Tabaei. Methylation and Polymorphism in CDH1 Gene Promoter Among Patients with Diffuse Gastric Cancer. //PubMed – 2022. – Т. 13. - №. 44. – P. 5-6.
48. Norihiko Sasaki, Seiichi Shinji, Yuuki Shichi, Toshiyuki Ishiwata, Tomio Arai, Takeshi Yamada, Goro Takahashi, Ryo Ohta, Hiromichi Sonoda, Akihisa Matsuda, Takuma Iwai, Kohki Takeda, Kazuhide Yonaga, Koji Ueda, Sho Kuriyama, Toshimitsu Miyasaka, Hiroshi Yoshida. TGF-β1 increases cellular invasion of colorectal neuroendocrine carcinoma cell line through partial epithelial-mesenchymal transition. //PubMed – 2022. – T. 30. – C. 3-5.
49. Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. – 2012. – T. 4. – №. 5.
50. Rodrigo Santa Cruz Guindalini, Marina Cândido Visontai Cormedi, Simone Maistro, Fátima Solange Pasini, Priscila Cristina Abduch Adas Branas, Liliane Dos Santos, Gláucia Fernanda de Lima Pereira, Geertruida Hendrika de Bock, Daniela Marques Saccaro, Maria Lucia Hirata Katayama, Sheila Friedrich Faraj, Adriana Safatle-Ribeiro, Ulysses Ribeiro Junior, Maria Del Pilar Estevez Diz, Ana Carolina Ribeiro Chaves de Gouvêa, Roger Chammas, Maria Aparecida Azevedo Koike Folgueira. Frequency of CDH1 germline variants and contribution of dietary habits in early age onset gastric cancer patients in Brazil. //PubMed – 2019. – P. 5-6.
51. Rodriguez FJ, Lewis-Tuffin LJ, Anastasiadis PZ. E-cadherin’s dark side: possible role in tumor progression. Biochim Biophys Acta. – 2012. – T. 182. – P. 623–631.
52. Sadjadi A. et al. Neglected role of hookah and opium in gastric carcinogenesis: a cohort study on risk factors and attributable fractions //International journal of cancer. – 2014. – Т. 134. – №. 1. – P. 181-188. 23
53. Shin S. et al. Frequency and Clinical Characteristics of Unselected Korean Gastric Cancer Patients with a Germline CDH1 V832M Mutation //Journal of Cancer. – 2020. – Т. 11. – №. 1. – P. 208.
54. Spolverato G., Ejaz A., Kim Y. et al. Use of endoscopic ultrasound in the preoperative staging of gastric cancer: a multi-institutional study of the US gastric cancer collaborative. J Am Coll Surg – 2015. – T. 220. – №. 1. – P. 48–56.
55. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. – 2015. – T. 64. – №. 9. – P. 353–367.
56. TaharaE. Genetic pathways of two types of gastric cancer // IARC Sci. Publ. – 2004. – P. 327-349.
57. Takahashi N., Yamada Y., Taniguchi H., et al. Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. BMC Res Notes. – 2014. – №. 7 – P. 271.
58. Takeshima H., Niwa T., Takahashi T., et al. Frequent involvement of chromatin remodeler alterations in gastric field cancerization. Cancer Lett. – 2015. – T. 357. – №. 1. – P. 328-338.
59. van der Post R. S. et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers //Journal of medical genetics. – 2015. – Т. 52. – №. 6. – P. 361-374.
60. Wang K., Kan J., Yuen S.T., et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. – 2011. – T. 43. - №.12– P. 1219-1223.
61. Wang K., Yuen S.T., Xu J., et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. – 2014. – Т. 46. - №. 6. – P. 573-582.
62. Woojin Kim, Trilokesh Kidambi, James Lin, Gregory Idos. Genetic Syndromes Associated with Gastric Cancer. – 2021. – T. 32 – P. 147-162.
63. Zang Z.J., Cutcutache I., Poon S.L., et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet. – 2012. – T. 44. - №. 5. - P. 570-574.
Форма заказа новой работы
Не подошла эта работа?
Закажи новую работу, сделанную по твоим требованиям
